Novel CLL Therapies Prompt New Treatment Considerations
- Now that targeted agents have "decisively" displaced chemoimmunotherapy as teh first-line standard of care in chronic lymphocytic leukemia (CLL), clinicians and patients have a new set of factors...
- In a new review article in the Nature Reviews Clinical Oncology, experts outline the evolving treatment landscape and provide guidance on selecting the optimal approach for individual patients.
- updates to national guidelines over the past 3 years have consistently centered on the use of targeted therapies, the authors noted.
Now that targeted agents have ”decisively” displaced chemoimmunotherapy as teh first-line standard of care in chronic lymphocytic leukemia (CLL), clinicians and patients have a new set of factors to consider when choosing a therapeutic regimen.
In a new review article in the Nature Reviews Clinical Oncology, experts outline the evolving treatment landscape and provide guidance on selecting the optimal approach for individual patients.
updates to national guidelines over the past 3 years have consistently centered on the use of targeted therapies, the authors noted. The recommended treatment options include continuous therapy with the selective Bruton’s tyrosine kinase (BTK) inhibitors acalabrutinib (Calquence; AstraZeneca) or zanubrutinib (Brukinsa; BeOne), or fixed-duration therapy with the BCL2 inhibitor venetoclax (Venclexta; Abbvie and Genentech) plus the CD20-directed obinutuzumab (Gazyva; Genentech) or the first-generation BTK inhibitor ibrutinib (Imbruvica; Pharmacyclics and Johnson & johnson), the authors said. In some regions, they noted, the recommendations now include fixed-duration venetoclax plus acalabrutinib with or without obinutuzumab.
As those therapies have begun to predominate CLL treatment, Davids and colleagues explained that previous generalized treatment algorithms have become less useful.
“Instead, selecting the optimal treatment for a patient requires evaluation and weighting of many factors,” they said. Key among those factors, they added, is patient preference
The authors noted that the benefits of first-line monotherapy with a BTK inhibitor are well-documented, producing durable results in both high- and low-risk patients. They added that ibrutinib and acalabrutinib can also be used in combination with obinutuzumab and rituximab (Rituxan; Genentech and Biogen), though they said it is not clear whether such combinations produce superior results to monotherapy with a BTK inhibitor.
In high-risk patients, continuous BTK inhibitor therapy is generally preferred, Davids and colleagues said.
Tumor Lysis Syndrome Management in CLL Treatment
Table of Contents
A study published in Blood in 2019 detailed the prevention and management of tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) receiving either venetoclax-obinutuzumab or chlorambucil-obinutuzumab, based on results from the randomized CLL14 trial.
Chronic Lymphocytic Leukemia (CLL) and Tumor Lysis Syndrome (TLS)
Chronic lymphocytic leukemia (CLL) is a type of cancer of the blood and bone marrow. The National Cancer Institute defines CLL as a slowly progressing leukemia that often affects older adults. Tumor lysis syndrome (TLS) is a perhaps life-threatening condition that can occur when a large number of cancer cells are killed off rapidly, releasing thier contents into the bloodstream.
TLS can lead to kidney failure, heart problems, and seizures. Patients undergoing treatment for CLL,particularly with highly effective therapies,are at risk of developing TLS. The CLL14 trial investigated strategies to mitigate this risk.
The CLL14 Trial and Treatment Regimens
The CLL14 trial was a randomized, open-label, phase 3 study comparing venetoclax plus obinutuzumab to chlorambucil plus obinutuzumab for the treatment of previously untreated CLL. The New England Journal of Medicine published the primary results of the CLL14 trial in 2018, demonstrating superior progression-free survival with the venetoclax-obinutuzumab combination.
The study, as reported in Blood in 2019, focused specifically on the management of TLS within the context of this trial. Two treatment regimens were evaluated:
- Venetoclax-Obinutuzumab: A combination of a BCL-2 inhibitor (venetoclax) and a monoclonal antibody (obinutuzumab).
- Chlorambucil-Obinutuzumab: A combination of a chemotherapy drug (chlorambucil) and a monoclonal antibody (obinutuzumab).
TLS prevention and Management Strategies
Effective TLS management involves both preventative measures and prompt treatment if TLS develops.The CLL14 trial implemented strategies including hydration, allopurinol (to reduce uric acid levels), and careful monitoring of electrolyte levels.
According to the UpToDate medical resource, key preventative measures include:
- Aggressive intravenous hydration
- Allopurinol or rasburicase to lower uric acid
- Monitoring of serum electrolytes, renal function, and phosphate levels
The Blood publication detailed the specific protocols used in the CLL14 trial and their effectiveness in minimizing TLS-related complications. As of January 24, 2026, no significant updates or corrections to the findings of this study have been published in major medical journals or reported by authoritative health organizations.